Image for representational purpose only. (Photo | AP) 
India

SII applies for full market authorisation of Covishield as supplies of vaccine exceeded 125 crore doses

SII had partnered with the developer of Covishield, AstraZeneca, for the supply of the vaccine to the Indian government

PTI

NEW DELHI: Serum Institute of India (SII) CEO Adar Poonawala on Friday said it has applied to Indian authorities for full market authorisation of Covishield, stating supplies of the COVID-19 vaccine have exceeded 125 crore doses.

SII had partnered with the developer of Covishield, AstraZeneca, for the supply of the vaccine to the Indian government, which had in January this year granted emergency use authorisation in the country.

"Supplies of the COVISHIELD vaccine in India, have exceeded 1.25 billion doses. The government of India now has enough data for full market authorisation, and therefore @SerumInstIndia has applied to the @CDSCO_INDIA_INF (DCGI) and @MoHFW_INDIA for this permission," Poonawala said in a tweet tagging the Central Drugs Standard Control Organisation (CDSCO) and Ministry of Health and Family Welfare.

'Sack Dharmendra Pradhan now': Rahul Gandhi demands PM Modi take accountability for NEET UG paper leak

CM Vijay keeps Home, Sengottaiyan gets Finance; Keerthana Industries; here's the list of TN ministers and portfolios

'Pained' by how media misquoted my observation: CJI Surya Kant issues clarification on 'parasite' remark

Weekly Review: Indian markets swayed by Crude rally and Rupee weakness

CBI arrests NTA biology expert; second paper-setting panel member detained in NEET paper leak probe

SCROLL FOR NEXT